Plans Phase 2b/3 Trial for Biologic in Prevention of Organ Dysfunction in ICU

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – February 7, 2013) BioAegis Therapeutics announced today that it completed it’s initial $3MM convertible note round to fund the companies operating activites in its effort to commercialize groundbreaking discoveries as to plasma gelsolin’s (pGSN) biological role in inflammation and infection. pGSN is the 4th most abundant protein in plasma and is highly conserved. Its depletion is highly predictive of adverse outcomes while its repletion in numerous animal models has been shown to prevent morbidity and mortality.